Consumption_NN of_IN Imipenem_NP Correlates_NP with_IN beta-Lactam_NP Resistance_NP in_IN Pseudomonas_NP aeruginosa_NP It_PP is_VBZ generally_RB assumed_VBN that_IN the_DT antibiotic_JJ prescription_NN policy_NN of_IN a_DT hospital_NN has_VBZ a_DT significant_JJ impact_NN on_IN bacterial_JJ resistance_NN rates_NNS ;_: however_RB ,_, few_JJ studies_NNS are_VBP available_JJ to_TO support_VB this_DT concept_NN with_IN valid_JJ statistical_JJ data_NNS ._SENT During_IN a_DT 3-year_JJ period_NN from_IN 1997_CD to_TO 2000_CD ,_, we_PP monitored_VBD the_DT consumption_NN of_IN beta-lactam_NN and_CC other_JJ antibiotics_NNS with_IN known_VBN activity_NN against_IN Pseudomonas_NP aeruginosa_NP in_IN a_DT 600-bed_JJ community_NN hospital_NN ._SENT Monthly_JJ isolations_NNS of_IN P._NP aeruginosa_NP were_VBD assessed_VBN ,_, and_CC resistance_NN rates_NNS were_VBD recorded_VBN ._SENT Partial_JJ correlation_NN coefficients_NNS between_IN consumption_NN and_CC resistance_NN rates_NNS were_VBD determined_VBN ,_, taking_VBG into_IN account_NN possible_JJ associations_NNS with_IN other_JJ variables_NNS such_JJ as_IN seasonal_JJ effects_NNS and_CC transfers_NNS from_IN other_JJ hospitals_NNS ._SENT A_DT total_NN of_IN 30_CD +-_NN 7_CD novel_NN P._NP aeruginosa_NP strains_NNS per_IN month_NN were_VBD isolated_VBN without_IN epidemic_NN clustering_VBG ._SENT Prescriptions_NNS of_IN imipenem_NN varied_VBN significantly_RB during_IN the_DT study_NN period_NN ,_, while_IN prescriptions_NNS of_IN other_JJ antipseudomonal_JJ agents_NNS were_VBD stable_JJ ,_, with_IN the_DT exception_NN of_IN an_DT increase_NN in_IN piperacillin-tazobactam_NN prescriptions_NNS ._SENT Rates_NNS of_IN resistance_NN of_IN P._NP aeruginosa_NP to_TO the_DT antimicrobial_JJ agents_NNS used_VBN showed_VBD a_DT time_NN course_NN similar_JJ to_TO figures_NNS for_IN imipenem_NN consumption_NN ._SENT Monthly_JJ rates_NNS of_IN resistance_NN to_TO imipenem_VB (_( partial_JJ correlation_NN coefficient_NN [_SYM cc_NN ]_SYM ,_, 0.63_CD )_) ,_, piperacillin-tazobactam_NP (_( cc_NP ,_, 0.57_CD )_) ,_, and_CC ceftazidime_JJ (_( cc_NN ,_, 0.56_CD )_) were_VBD significantly_RB associated_VBN with_IN imipenem_NN prescription_NN rates_NNS in_IN the_DT same_JJ or_CC the_DT preceding_JJ month_NN ,_, while_IN consumption_NN of_IN ceftazidime_NN or_CC piperacillin-tazobactam_NN had_VBD no_DT apparent_JJ association_NN with_IN resistance_NN ._SENT Among_IN the_DT variables_NNS investigated_VBD ,_, imipenem_NN consumption_NN was_VBD identified_VBN as_IN the_DT major_JJ factor_NN associated_VBN with_IN both_DT carbapenem_NN and_CC beta-lactam_NN resistance_NN in_IN endemic_JJ P._NP aeruginosa_NP ._SENT Periods_NNS of_IN extensive_JJ imipenem_NN use_NN were_VBD associated_VBN with_IN significant_JJ increases_NNS in_IN resistance_NN ._SENT Our_PP$ data_NNS support_VBP the_DT concept_NN that_IN a_DT written_JJ antibiotic_JJ policy_NN which_WDT balances_VBZ the_DT use_NN of_IN various_JJ antibiotic_JJ classes_NNS may_MD help_VB to_TO avoid_VB disturbances_NNS of_IN a_DT hospital_NN 's_POS microbial_JJ sensitivity_NN patterns_NNS ._SENT Pseudomonas_NP aeruginosa_NP is_VBZ a_DT major_JJ pathogen_NN in_IN nosocomial_JJ infections_NNS ,_, ranking_VBG second_JJ only_RB to_TO Staphylococcus_NP aureus_NN in_IN a_DT recent_JJ multicenter_NN study_NN of_IN infections_NNS in_IN European_JJ intensive_JJ care_NN units_NNS ._SENT The_DT organism_NN may_MD be_VB involved_VBN in_IN respiratory_JJ ,_, urinary_JJ ,_, wound_NN ,_, and_CC bloodstream_NN infections_NNS ,_, primarily_RB in_IN patients_NNS with_IN severe_JJ underlying_VBG diseases_NNS or_CC impaired_JJ immune_JJ defense_NN ._SENT Since_IN the_DT lethality_NN of_IN P._NP aeruginosa_NP infections_NNS is_VBZ high_JJ once_IN the_DT organism_NN has_VBZ caused_VBN disseminated_VBN disease_NN ,_, early_JJ and_CC adequate_JJ antibiotic_JJ therapy_NN is_VBZ essential_JJ ._SENT Resistance_NN of_IN P._NP aeruginosa_NP to_TO antimicrobials_NNS used_VBN for_IN primary_JJ treatment_NN has_VBZ been_VBN shown_VBN to_TO correlate_VB with_IN an_DT adverse_JJ clinical_JJ outcome_NN ._SENT While_IN the_DT incidence_NN and_CC risk_NN factors_NNS for_IN the_DT development_NN of_IN antibiotic_JJ resistance_NN in_IN P._NP aeruginosa_NP have_VBP been_VBN studied_VBN repeatedly_RB in_IN cohort_NN studies_NNS or_CC comparative_JJ studies_NNS evaluating_VBG the_DT effects_NNS of_IN novel_NN antibiotics_NNS ,_, little_RB is_VBZ known_VBN about_IN the_DT influence_NN of_IN a_DT hospital_NN 's_POS antibiotic_JJ policy_NN on_IN resistance_NN epidemiology_NN in_IN the_DT hospital_NN as_IN a_DT whole_NN ._SENT In_IN a_DT 600-bed_JJ community_NN hospital_NN ,_, we_PP had_VBD the_DT opportunity_NN to_TO observe_VB significant_JJ changes_NNS in_IN the_DT prescription_NN rates_NNS of_IN antipseudomonal_JJ beta-lactam_NN drugs_NNS over_IN a_DT 3-year_JJ period_NN ,_, which_WDT coincided_VBD with_IN obvious_JJ variations_NNS in_IN resistance_NN ._SENT Bacteriology_NN ._SENT |_SYM P._NP aeruginosa_NP was_VBD identified_VBN biochemically_RB from_IN routinely_RB obtained_VBN specimens_NNS by_IN means_NNS of_IN the_DT the_DT Vitek_NP ATB_NP Expression_NP System_NP ,_, version_NN 2.7.8_CD (_( BioMerieux_NP Deutschland_NP GmbH_NP ,_, Nurtingen_NP ,_, Germany_NP )_) ,_, which_WDT uses_VBZ 32_CD biochemical_JJ reactions_NNS ._SENT Antibiotic_JJ susceptibility_NN testing_NN was_VBD performed_VBN by_IN the_DT same_JJ system_NN ,_, using_VBG a_DT microbroth_JJ breakpoint_NN dilution_NN technique_NN with_IN an_DT inoculum_NN of_IN 5_CD x_NN 105_CD organisms_NNS per_IN ml_NN and_CC a_DT test_NN volume_NN of_IN 135_CD mul_NN in_IN 18-well_NP microtiter_NN trays_NNS ._SENT MICs_NNS of_IN the_DT drugs_NNS were_VBD read_VBN automatically_RB after_IN aerobic_JJ incubation_NN at_IN 35C_JJ for_IN 18_CD to_TO 24_CD h._NNS The_DT susceptibility_NN breakpoints_NNS (_( susceptible_JJ and_CC resistant_JJ ,_, respectively_RB ,_, in_IN milligrams_NNS per_IN liter_NN )_) for_IN P._NP aeruginosa_NP were_VBD those_DT of_IN the_DT German_JJ National_NP Standard_NP :_: <=2_and =8_NN for_IN imipenem_NN ,_, <=4_and =32_NN for_IN ceftazidime_NN ,_, and_CC <=4_and =64_NN for_IN piperacillin_NN (_( in_IN the_DT presence_NN of_IN 4_CD mg_NN of_IN tazobactam/liter_NN )_) ._SENT For_IN comparison_NN ,_, breakpoints_NNS of_IN the_DT National_NP Committee_NP for_IN Clinical_NP Laboratory_NP Standards_NP (_( NCCLS_NP )_) are_VBP as_RB follows_VBZ :_: <=4_and =16_NN for_IN imipenem_NN ,_, <=8_and =32_NN for_IN ceftazidime_NN ,_, and_CC <=64_and =128_NN for_IN piperacillin_NN in_IN the_DT presence_NN of_IN 4_CD mg_NN of_IN tazobactam/liter_NN ._SENT Susceptibility_NN data_NNS were_VBD recorded_VBN monthly_RB using_VBG a_DT computer-based_JJ laboratory_NN documentation_NN system_NN (_( Medat_NP Software_NP ,_, Munich_NP ,_, Germany_NP )_) ._SENT The_DT system_NN is_VBZ adjusted_VBN to_TO count_VB only_RB primary_JJ isolates_NNS from_IN individual_JJ patients_NNS ,_, but_CC to_TO include_VB follow-up_NN isolates_NNS if_IN the_DT primary_JJ isolates_NNS show_VBP a_DT different_JJ pattern_NN of_IN antibiotic_JJ resistance_NN ._SENT Antibiotic_JJ consumption_NN ._SENT |_SYM Antibiotic_JJ deliveries_NNS to_TO the_DT hospital_NN were_VBD recorded_VBN in_IN the_DT clinical_JJ pharmacy_NN on_IN a_DT monthly_JJ basis_NN using_VBG a_DT computer-based_JJ pharmacy_NN documentation_NN system_NN ._SENT Deliveries_NNS could_MD be_VB assumed_VBN to_TO reflect_VB usage_NN because_IN the_DT supply_NN of_IN pharmacy_NN items_NNS to_TO the_DT wards_NNS was_VBD maintained_VBN continuously_RB by_IN the_DT "_`` Pharmacy_NP Stock_NP Control_NP (_( top-up_NN )_) "_`` system_NN ._SENT This_DT system_NN is_VBZ based_VBN on_IN an_DT inventory_NN or_CC stock_NN list_NN placed_VBN on_IN the_DT ward_NN ,_, describing_VBG the_DT contents_NNS and_CC optimum_JJ stock_NN levels_NNS of_IN all_DT trays_NNS and_CC baskets_NNS ,_, including_VBG correct_JJ locations_NNS ._SENT The_DT labels_NNS on_IN each_DT tray_NN and_CC basket_NN indicate_VBP the_DT contents_NNS by_IN bar_NN code_NN and_CC in_IN writing_NN ._SENT A_DT member_NN of_IN the_DT pharmacy_NN staff_NN visits_VBZ the_DT wards_NNS three_CD times_NNS a_DT week_NN (_( for_IN wards_NNS with_IN known_VBN high_JJ drug_NN turnover_NN )_) or_CC twice_RB a_DT week_NN (_( wards_NNS with_IN low_JJ drug_NN turnover_NN )_) and_CC checks_VBZ the_DT entire_JJ cupboard_NN for_IN the_DT presence_NN of_IN bar_NN codes_NNS ,_, pharmacy_NN requirements_NNS ,_, expiration_NN dates_NNS of_IN drugs_NNS ,_, and_CC recent_JJ changes_NNS in_IN prescribing_VBG ._SENT Thus_RB ,_, in_IN the_DT same_JJ way_NN as_IN all_DT other_JJ drugs_NNS ,_, antibiotics_NNS that_WDT had_VBD been_VBN ordered_VBN but_CC not_RB used_VBN were_VBD returned_VBN to_TO the_DT pharmacy_NN within_IN the_DT same_JJ week_NN ,_, and_CC supplies_NNS were_VBD delivered_VBN within_IN 24_CD h_NN after_IN the_DT visit_NN of_IN the_DT pharmacist_NN ._SENT Gram_NN amounts_NNS of_IN antibiotics_NNS were_VBD converted_VBN to_TO "_`` defined_VBN daily_JJ doses_NNS "_'' (_( DDDs_NP )_) by_IN using_VBG the_DT daily_JJ doses_NNS most_RBS frequently_RB prescribed_VBN in_IN this_DT hospital_NN ,_, which_WDT were_VBD as_RB follows_VBZ :_: imipenem_NN ,_, 3_CD g_NN ;_: piperacillin_NP ,_, 12_CD g_NN ,_, and_CC tazobactam_NN ,_, 1.5_CD g_NN ;_: ceftazidime_NN ,_, 6_CD g_NN ;_: gentamicin_NN and_CC tobramycin_NN ,_, 0.24_CD g_NN ;_: amikacin_NP ,_, 1_CD g_NN ;_: ceftriaxone_NN ,_, 2_CD g_NN ;_: cefotaxime_NN ,_, 6_CD g_NN ;_: intravenous_JJ ciprofloxacin_NN ,_, 0.4_CD g_NN ;_: oral_JJ ciprofloxacin_NN ,_, 1.0_NP g._FW Statistics_NP ._SENT |_SYM The_DT time_NN series_NN of_IN resistance_NN to_TO imipenem_NN ,_, ceftazidime_NN ,_, and_CC piperacillin-tazobactam_NN were_VBD cross-correlated_VBN with_IN the_DT corresponding_JJ time_NN series_NN for_IN use_NN of_IN the_DT drugs_NNS in_IN the_DT same_JJ period_NN ._SENT Associations_NNS were_VBD quantified_VBN using_VBG nonpartial_JJ and_CC partial_JJ correlation_NN coefficients_NNS according_VBG to_TO Pearson_NP and_CC Spearman_NP ,_, assuming_VBG a_DT lag_NN of_IN 1_CD month_NN between_IN use_NN and_CC resistance_NN ,_, and_CC assuming_VBG no_DT delay_NN in_IN between_IN ._SENT In_IN this_DT context_NN ,_, a_DT partial_JJ correlation_NN between_IN the_DT use_NN of_IN and_CC resistance_NN to_TO a_DT beta-lactam_NN means_VBZ that_IN seasonal_JJ effects_NNS ,_, patient_JJ transfers_NNS from_IN other_JJ hospitals_NNS ,_, and_CC the_DT use_NN of_IN other_JJ antibiotics_NNS with_IN activity_NN against_IN P._NP aeruginosa_NP were_VBD eliminated_VBN from_IN the_DT association_NN ._SENT For_IN example_NN ,_, in_IN estimating_VBG the_DT association_NN between_IN ceftazidime_NN resistance_NN and_CC imipenem_NN use_VBP 1_CD month_NN earlier_RBR ,_, adjustments_NNS were_VBD made_VBN for_IN the_DT use_NN of_IN ciprofloxacin_NN ,_, gentamicin_NN ,_, tobramycin_NP ,_, piperacillin-tazobactam_NN ,_, and_CC ceftazidime_JJ 1_CD month_NN earlier_RBR ._SENT P_NN values_NNS refer_VBP to_TO testing_VBG to_TO rule_VB out_RP the_DT possibility_NN that_IN the_DT indicated_JJ coefficients_NNS were_VBD equal_JJ to_TO zero_CD ._SENT In_IN a_DT further_JJR analysis_NN ,_, we_PP modeled_VBD the_DT dynamic_JJ relationship_NN between_IN antimicrobial_JJ use_NN and_CC resistance_NN by_IN using_VBG the_DT time_NN series_NN method_NN of_IN Box_NP and_CC Jenkins_NP as_RB described_VBD by_IN Lopez-Lozano_NP et_FW al._FW ._SENT Here_RB ,_, each_DT of_IN the_DT antibiotic_JJ use_NN series_NN was_VBD modeled_VBN by_IN an_DT autoregressive_NN low-order_JJ time_NN series_NN ._SENT Then_RB transfer_VB functions_NNS between_IN resistance_NN ,_, as_IN the_DT response_NN variable_NN ,_, and_CC the_DT use_NN series_NN ,_, seasonal_JJ effects_NNS ,_, and_CC patient_JJ transfers_NNS from_IN other_JJ hospitals_NNS were_VBD identified_VBN ._SENT Percentages_NNS of_IN resistance_NN among_IN isolates_NNS were_VBD compared_VBN by_IN a_DT two-sided_JJ chi-square_NN test_NN ._SENT All_DT statistical_JJ tests_NNS in_IN this_DT paper_NN are_VBP exploratory_JJ ,_, not_RB confirmatory_JJ ._SENT Hospital_NN setting_NN ._SENT |_SYM The_DT 600-bed_JJ acute-care_NN community_NN hospital_NN serves_VBZ a_DT city_NN of_IN 40,993_CD inhabitants_NNS with_IN a_DT surrounding_VBG community_NN of_IN more_JJR than_IN 200,000_CD inhabitants_NNS ._SENT All_DT major_JJ medical_JJ and_CC surgical_JJ disciplines_NNS are_VBP represented_VBN ._SENT During_IN the_DT study_NN period_NN ,_, 19,000_CD to_TO 20,000_CD patients_NNS were_VBD admitted_VBN every_DT year_NN ,_, and_CC fewer_JJR than_IN 3_CD %_NN were_VBD transfers_NNS from_IN other_JJ hospitals_NNS ._SENT On_IN average_NN ,_, 30_CD novel_NN P._NP aeruginosa_NP strains_NNS were_VBD isolated_VBN every_DT month_NN without_IN epidemic_NN clustering_VBG ._SENT Use_NN of_IN antipseudomonal_JJ antibiotics_NNS ._SENT |_SYM Among_IN the_DT antipseudomonal_JJ drugs_NNS ,_, non-beta-lactam_NN antibiotics_NNS were_VBD used_VBN at_IN a_DT rather_RB constant_JJ rate_NN during_IN the_DT study_NN period_NN ,_, with_IN monthly_JJ prescription_NN rates_NNS (_( DDDs_NP per_IN month_NN +-_NN 1_CD standard_NN deviation_NN )_) of_IN 296.13_CD +-_NN 59.0_CD g_NN (_( ciprofloxacin_NN )_) ,_, 125.8_CD +-_NN 40.0_CD g_NN (_( gentamicin_NN )_) ,_, and_CC 56.7_CD +-_NN 40.0_CD g_NN (_( tobramycin_NN )_) ._SENT Netilmicin_NP was_VBD not_RB used_VBN ,_, and_CC amikacin_NN consumption_NN was_VBD close_JJ to_TO zero_VB because_IN this_DT drug_NN was_VBD used_VBN for_IN exceptional_JJ cases_NNS only_RB ._SENT Therefore_RB ,_, figures_NNS for_IN amikacin_NN were_VBD not_RB taken_VBN into_IN account_NN in_IN statistical_JJ evaluations_NNS ._SENT Among_IN the_DT antipseudomonal_JJ beta-lactams_NNS ,_, ceftazidime_NN use_NN was_VBD low_JJ and_CC stable_JJ during_IN the_DT study_NN period_NN ,_, while_IN use_NN of_IN piperacillin-tazobactam_NN increased_VBD ._SENT Ciprofloxacin_NP was_VBD the_DT only_JJ quinolone_NN used_VBN in_IN this_DT hospital_NN ._SENT Striking_JJ variations_NNS were_VBD noted_VBN for_IN the_DT use_NN of_IN imipenem_NN ,_, which_WDT was_VBD the_DT only_JJ carbapenem_NN used_VBN during_IN the_DT study_NN period_NN ._SENT In_IN fact_NN ,_, even_RB when_WRB expanded-spectrum_NN cephalosporins_NNS other_JJ than_IN ceftazidime_NN were_VBD taken_VBN into_IN account_NN ,_, imipenem_NN use_NN was_VBD the_DT major_JJ factor_NN determining_VBG overall_JJ parenteral_JJ antibiotic_JJ consumption_NN ._SENT Increasing_VBG consumption_NN of_IN imipenem_NN during_IN the_DT first_JJ half_NN of_IN 1998_CD coincided_VBD with_IN a_DT marketing_NN campaign_NN by_IN the_DT manufacturer_NN ,_, who_WP presented_VBD data_NNS showing_VBG that_DT primary_JJ therapy_NN of_IN nosocomial_JJ pneumonia_NN ,_, secondary_JJ peritonitis_NN ,_, and_CC other_JJ infections_NNS with_IN imipenem_NN led_VBN to_TO significant_JJ cost_NN savings_NNS ._SENT Reprints_NNS and_CC summaries_NNS of_IN these_DT studies_NNS were_VBD distributed_VBN to_TO hospital_NN physicians_NNS by_IN a_DT representative_NN of_IN the_DT manufacturer_NN ._SENT Resistance_NN of_IN P._NP aeruginosa_NP to_TO imipenem_NN ._SENT |_SYM Shortly_RB after_IN the_DT intensified_JJ use_NN of_IN imipenem_NN ,_, we_PP noted_VBD a_DT dramatic_JJ increase_NN in_IN the_DT resistance_NN of_IN P._NP aeruginosa_NP isolates_VBZ to_TO this_DT drug_NN ._SENT In_IN the_DT early_JJ summer_NN of_IN 1998_CD ,_, the_DT infection_NN control_NN and_CC antimicrobial_JJ committees_NNS of_IN the_DT hospital_NN expressed_VBD concern_NN regarding_VBG increasing_JJ resistance_NN of_IN P._NP aeruginosa_NP to_TO imipenem_NN and_CC increasing_VBG use_NN of_IN this_DT drug_NN ._SENT Analysis_NN of_IN hospital_NN microbiology_NN data_NNS revealed_VBD no_DT objective_JJ need_NN for_IN an_DT intensified_JJ use_NN of_IN imipenem_NN ,_, because_IN there_EX was_VBD no_DT increase_NN in_IN the_DT number_NN of_IN P._NP aeruginosa_NP isolates_NNS or_CC organisms_NNS belonging_VBG to_TO other_JJ species_NNS that_WDT would_MD have_VB been_VBN sensitive_JJ to_TO carbapenems_NNS only_RB ._SENT Therefore_RB ,_, it_PP was_VBD decided_VBN that_IN imipenem_NN should_MD not_RB be_VB delivered_VBN by_IN the_DT pharmacy_NN unless_IN written_JJ prescription_NN forms_NNS were_VBD filled_VBN out_IN stating_VBG the_DT reason_NN why_WRB other_JJ drugs_NNS could_MD not_RB be_VB used_VBN (_( e.g._FW ,_, because_IN of_IN microbiologically_RB documented_VBN resistance_NN )_) ._SENT Furthermore_RB ,_, prescriptions_NNS had_VBD to_TO be_VB countersigned_VBN by_IN the_DT chief_NN or_CC vice-chief_NN of_IN the_DT respective_JJ clinical_JJ department_NN ._SENT Following_VBG this_DT decision_NN ,_, imipenem_NN use_NN decreased_VBD rapidly_RB ,_, as_RB did_VBD resistance_NN rates_NNS ._SENT At_IN the_DT end_NN of_IN the_DT observation_NN period_NN ,_, after_IN the_DT restrictions_NNS had_VBD been_VBN loosened_VBN ,_, the_DT use_NN of_IN imipenem_NN increased_VBN again_RB ._SENT Over_IN the_DT whole_JJ study_NN period_NN ,_, imipenem_NN consumption_NN correlated_VBD significantly_RB with_IN imipenem_NN resistance_NN ,_, with_IN a_DT (_( nonpartial_JJ )_) correlation_NN coefficient_NN of_IN 0.63_CD (_( P_NN <=_NN 0.05_CD )_) ._SENT This_DT correlation_NN was_VBD seen_VBN not_RB only_RB when_WRB monthly_JJ prescription_NN rates_NNS were_VBD compared_VBN with_IN resistance_NN data_NNS from_IN the_DT same_JJ month_NN ,_, but_CC also_RB with_IN those_DT of_IN the_DT following_VBG month_NN ._SENT By_IN contrast_NN ,_, correlation_NN coefficients_NNS dropped_VBD to_TO insignificant_JJ levels_NNS when_WRB other_JJ time_NN lags_NNS between_IN use_NN and_CC resistance_NN were_VBD used_VBN for_IN calculation_NN ._SENT Resistance_NN of_IN P._NP aeruginosa_NP to_TO beta-lactams_NNS ._SENT |_SYM Piperacillin-tazobactam_NP was_VBD used_VBN more_RBR frequently_RB for_IN empirical_JJ therapy_NN after_IN July_NP 1998_CD ,_, with_IN monthly_JJ prescriptions_NNS rising_VBG from_IN 28.2_CD DDDs_NP in_IN July_NP 1997_CD to_TO 153.8_CD DDDs_NP in_IN February_NP 1999_CD ._SENT Mean_JJ monthly_JJ prescriptions_NNS during_IN the_DT first_JJ period_NN of_IN high_JJ imipenem_NN use_NN (_( September_NP 1997_CD to_TO May_NP 1998_CD )_) were_VBD 68.9_CD +-_NN 11.8_CD DDDs_NNS per_IN month_NN ,_, compared_VBN with_IN 106.0_CD +-_NN 39.5_CD DDDs_NNS per_IN month_NN during_IN the_DT period_NN of_IN low_JJ imipenem_NN use_NN (_( June_NP 1998_CD to_TO December_NP 1999_CD )_) ._SENT Despite_IN increasing_VBG use_NN ,_, no_DT correlation_NN was_VBD seen_VBN between_IN consumption_NN of_IN this_DT drug_NN and_CC resistance_NN ._SENT By_IN contrast_NN ,_, both_DT resistance_NN to_TO ceftazidime_NN and_CC resistance_NN to_TO piperacillin-tazobactam_NN showed_VBD time_NN courses_NNS similar_JJ to_TO that_DT of_IN imipenem_NN consumption_NN ,_, with_IN peak_NN ceftazidime_NN resistance_NN rates_NNS of_IN 42_CD %_NN and_CC peak_NN piperacillin-tazobactam_NN resistance_NN rates_NNS of_IN 25_CD %_NN during_IN the_DT period_NN of_IN maximum_JJ imipenem_NN consumption_NN in_IN 1998_CD (_( data_NNS not_RB shown_VBN )_) ._SENT Partial_JJ correlation_NN coefficients_NNS for_IN imipenem_NN consumption_NN and_CC resistance_NN revealed_VBD significant_JJ statistical_JJ associations_NNS between_IN imipenem_NN use_NN and_CC resistance_NN to_TO ceftazidime_NN or_CC piperacillin-tazobactam_NN ._SENT Time_NN series_NN analysis_NN ._SENT |_SYM Results_NNS similar_JJ to_TO those_DT indicated_VBN by_IN the_DT Pearson_NP coefficients_NNS were_VBD obtained_VBN by_IN calculating_VBG Spearman_NP 's_POS rank_JJ coefficients_NNS (_( data_NNS not_RB shown_VBN )_) and_CC by_IN using_VBG time_NN series_NN modeling_NN according_VBG to_TO the_DT work_NN of_IN Box_NP and_CC Jenkins_NP ._SENT When_WRB modeling_VBG imipenem_NN resistance_NN ,_, we_PP found_VBD positive_JJ regression_NN coefficients_NNS quantifying_VBG an_DT association_NN with_IN imipenem_NN use_NN in_IN the_DT same_JJ month_NN (_( P_NN <_SYM 0.1_CD )_) as_IN well_RB as_RB with_IN use_NN during_IN the_DT preceding_JJ month_NN (_( P_NN <_SYM 0.05_CD )_) ._SENT The_DT same_JJ was_VBD true_JJ when_WRB we_PP checked_VBD the_DT dependence_NN of_IN ceftazidime_NN resistance_NN (_( P_NN <_SYM 0.06_CD )_) and_CC piperacillin-tazobactam_NN resistance_NN (_( P_NN <_0.01) 300_CD DDDs_NNS per_IN month_NN ,_, a_DT total_NN of_IN 183_CD isolates_NNS from_IN various_JJ wards_NNS were_VBD isolated_VBN ,_, 39_CD (_( 21.3_CD %_NN )_) of_IN which_WDT were_VBD secondary_JJ isolates_NNS ._SENT Thirteen_CD of_IN 144_CD (_( 9.0_CD %_NN )_) primary_JJ isolates_NNS were_VBD resistant_JJ to_TO imipenem_NN ,_, compared_VBN with_IN 21_CD of_IN 39_CD (_( 53.8_CD %_NN )_) secondary_JJ isolates_NNS (_( P_NN <_SYM 0.01_CD by_IN the_DT chi-square_NN test_NN )_) ._SENT This_DT shows_VBZ that_IN resistance_NN was_VBD not_RB due_JJ to_TO an_DT epidemic_NN of_IN primary_JJ imipenem-resistant_JJ isolates_NNS during_IN this_DT period_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Overall_JJ use_NN of_IN major_JJ parenteral_JJ antibiotics_NNS during_IN the_DT 3-year_JJ period_NN examined_VBN ,_, expressed_VBN as_IN DDDs_NP per_IN month_NN for_IN bimonthly_JJ intervals_NNS ._SENT Overall_JJ use_NN of_IN major_JJ parenteral_JJ antibiotics_NNS during_IN the_DT 3-year_JJ period_NN examined_VBN ,_, expressed_VBN as_IN DDDs_NP per_IN month_NN for_IN bimonthly_JJ intervals_NNS ._SENT Figures_NNS for_IN ciprofloxacin_NN include_VBP oral_JJ administrations_NNS ._SENT The_DT term_NN "_`` cephalosporins_NNS "_`` refers_VBZ to_TO ceftriaxone_NN and_CC cefotaxime_NN ._SENT FIG._NN 2_CD ._SENT |_SYM Correlation_NN between_IN consumption_NN of_IN imipenem_NN and_CC resistance_NN of_IN P._NP aeruginosa_NP Correlation_NP between_IN consumption_NN of_IN imipenem_NN and_CC resistance_NN of_IN P._NP aeruginosa_NP to_TO imipenem_NN ._SENT (_( A_NP )_) Bimonthly_NP resistance_NN rates_NNS plotted_VBN against_IN bimonthly_JJ consumption_NN rates_NNS for_IN a_DT 3-year_JJ period_NN ._SENT (_( B_NP )_) Relation_NN between_IN monthly_JJ imipenem_NN consumption_NN and_CC resistance_NN in_IN the_DT month_NN of_IN consumption_NN for_IN the_DT whole_JJ 3-year_JJ period_NN ._SENT (_( C_LS )_) Nonpartial_JJ correlation_NN coefficients_NNS between_IN monthly_JJ imipenem_NN consumption_NN and_CC resistance_NN in_IN the_DT month_NN of_IN consumption_NN (_( designated_VBN "_`` 0_CD "_'' )_) and_CC the_DT 2_CD months_NNS prior_RB to_TO and_CC following_VBG consumption_NN ._SENT Asterisks_NNS indicate_VBP statistical_JJ significance_NN (_( P_NN <_SYM 0.005_CD )_) ._SENT TABLE_NN 1_CD |_SYM Monthly_JJ admissions_NNS ,_, transfers_NNS ,_, and_CC P._NP aeruginosa_NP strains_NNS isolated_VBN TABLE_NP 2_CD |_SYM Correlations_NNS between_IN antibiotic_JJ consumption_NN and_CC resistance_NN of_IN P._NP aeruginosa_NP Although_IN it_PP is_VBZ often_RB said_VBN that_IN the_DT pattern_NN of_IN antibiotic_JJ resistance_NN in_IN a_DT given_VBN hospital_NN is_VBZ nothing_NN but_CC the_DT negative_JJ imprint_NN of_IN the_DT antibiotic_JJ prescription_NN behavior_NN in_IN that_DT hospital_NN ,_, few_JJ valid_JJ statistical_JJ data_NNS are_VBP available_JJ to_TO substantiate_VB this_DT assumption_NN ._SENT For_IN some_DT organisms_NNS ,_, such_JJ as_IN quinolone-resistant_JJ Escherichia_NP coli_NNS ,_, vancomycin-resistant_JJ enterococci_NNS ,_, or_CC quinolone-resistant_JJ coagulase-negative_JJ staphylococci_NNS ,_, relationships_NNS have_VBP been_VBN established_VBN between_IN consumption_NN rates_NNS of_IN the_DT respective_JJ drugs_NNS and_CC the_DT increasing_VBG isolation_NN rates_NNS of_IN resistant_JJ organisms_NNS in_IN individual_JJ hospitals_NNS ._SENT However_RB ,_, the_DT association_NN is_VBZ less_RBR convincing_JJ for_IN the_DT use_NN of_IN broad-spectrum_NN beta-lactam_NN agents_NNS in_IN relation_NN to_TO the_DT epidemiology_NN of_IN resistance_NN of_IN common_JJ gram-negative_JJ bacteria_NNS ._SENT In_IN a_DT recent_JJ prospective_JJ study_NN involving_VBG eight_CD U.S._NP hospitals_NNS ,_, it_PP was_VBD not_RB possible_JJ to_TO find_VB an_DT association_NN of_IN consumption_NN with_IN resistance_NN for_IN individual_JJ antimicrobial-agent-organism_NN pairs_NNS ._SENT It_PP was_VBD speculated_VBN that_IN other_JJ factors_NNS ,_, such_JJ as_IN interhospital_JJ transfer_NN of_IN resistance_NN due_JJ to_TO patient_JJ transfers_NNS ,_, a_DT community_NN contribution_NN to_TO resistance_NN ,_, or_CC a_DT complex_JJ relationship_NN between_IN resistance_NN and_CC the_DT use_NN of_IN a_DT variety_NN of_IN antimicrobial_JJ agents_NNS ,_, might_MD have_VB acted_VBN as_IN confounding_VBG variables_NNS ._SENT Thus_RB ,_, the_DT question_NN of_IN whether_IN the_DT control_NN of_IN antibiotic_JJ prescriptions_NNS by_IN infectious-disease_NN specialists_NNS (_( ;_: R._NP P._NP Wenzel_NP ,_, Editorial_NP ,_, Clin_NP ._SENT Infect_JJ ._SENT Dis_NPS ._SENT 24:456_CD ,_, 1997_CD )_) or_CC the_DT scheduled_VBN cycling_NN of_IN antibiotics_NNS in_IN high-risk_JJ areas_NNS such_JJ as_IN intensive-care_NN units_NNS is_VBZ appropriate_JJ for_IN reducing_VBG resistance_NN rates_NNS is_VBZ still_RB a_DT matter_NN of_IN controversy_NN ._SENT In_IN the_DT hospital_NN described_VBD here_RB ,_, several_JJ of_IN the_DT confounders_NNS just_RB mentioned_VBN were_VBD virtually_RB absent_JJ ._SENT Although_IN some_DT specialized_JJ outpatient_NN services_NNS were_VBD offered_VBN ,_, these_DT did_VBD not_RB include_VB patient_JJ groups_NNS likely_JJ to_TO carry_VB drug-resistant_JJ P._NP aeruginosa_NP ._SENT As_IN shown_VBN in_IN Table_NP ,_, transfers_NNS from_IN other_JJ hospitals_NNS accounted_VBN for_IN less_JJR than_IN 3_CD %_NN of_IN total_JJ admissions_NNS ,_, which_WDT excludes_VBZ a_DT significant_JJ impact_NN of_IN antibiotic-resistant_JJ strains_NNS from_IN other_JJ institutions_NNS on_IN this_DT hospital_NN 's_POS ecology_NN ._SENT The_DT epidemiology_NN of_IN P._NP aeruginosa_NP was_VBD characterized_VBN by_IN regular_JJ isolations_NNS of_IN this_DT organism_NN at_IN a_DT low_JJ but_CC rather_RB constant_JJ rate_NN ,_, reflecting_VBG a_DT situation_NN of_IN endemicity_NN ._SENT It_PP has_VBZ been_VBN shown_VBN previously_RB that_IN about_RB one-half_JJ of_IN endemically_RB occurring_VBG nosocomial_JJ P._NP aeruginosa_NP infections_NNS or_CC colonizations_NNS are_VBP due_JJ to_TO horizontal_JJ transmissions_NNS of_IN the_DT organism_NN between_IN patients_NNS ,_, e.g._FW ,_, via_IN fomites_NNS ,_, fingernails_NNS of_IN the_DT personnel_NNS ,_, or_CC water_NN from_IN contaminated_JJ sinks_NNS ._SENT In_IN the_DT setting_NN described_VBD here_RB ,_, horizontal_JJ transmissions_NNS may_MD have_VB acted_VBN as_IN an_DT amplifier_NN of_IN individual_JJ molecular_JJ events_NNS leading_VBG to_TO resistance_NN ._SENT Nevertheless_RB ,_, a_DT significant_JJ association_NN between_IN antibiotic_JJ exposures_NNS and_CC resistance_NN at_IN a_DT level_NN affecting_VBG the_DT whole_JJ hospital_NN would_MD not_RB have_VB been_VBN detected_VBN had_VBD there_RB not_RB been_VBN enormous_JJ variations_NNS in_IN the_DT consumption_NN of_IN imipenem_NN during_IN the_DT 3-year_JJ period_NN examined_VBD ._SENT These_DT variations_NNS were_VBD difficult_JJ to_TO explain_VB ,_, because_IN there_EX were_VBD no_DT apparent_JJ changes_NNS in_IN the_DT spectrum_NN of_IN patients_NNS treated_VBN or_CC the_DT monthly_JJ number_NN of_IN admissions_NNS ._SENT The_DT primary_JJ use_NN of_IN carbapenems_NNS for_IN empirical_JJ therapy_NN of_IN nosocomial_JJ infections_NNS was_VBD supported_VBN by_IN various_JJ opinion_NN leaders_NNS in_IN Germany_NP since_IN the_DT mid-1990s_NNS ,_, and_CC studies_NNS apparently_RB proving_VBG a_DT superior_JJ clinical_JJ cure_NN rate_NN achievable_JJ with_IN imipenem_NN compared_VBN to_TO broad-spectrum_NN cephalosporins_NNS or_CC penicillins_NNS appeared_VBD in_IN 1997_CD and_CC 1998_CD ._SENT According_VBG to_TO these_DT publications_NNS ,_, the_DT less_RBR frequent_JJ need_NN to_TO switch_VB to_TO other_JJ antibiotic_JJ regimens_NNS and_CC the_DT shorter_JJR overall_JJ hospital_NN stay_NN of_IN carbapenem-treated_NN patients_NNS led_VBN to_TO significant_JJ cost_NN savings_NNS ._SENT Issues_NNS of_IN drug_NN resistance_NN were_VBD not_RB addressed_VBN in_IN these_DT reports_NNS ._SENT Because_IN drug_NN orders_NNS in_IN our_PP$ hospital_NN were_VBD served_VBN by_IN the_DT pharmacy_NN without_IN requests_NNS for_IN authorization_NN ,_, we_PP hypothesize_VBP that_IN these_DT publications_NNS promoted_VBD the_DT intensified_JJ use_NN of_IN imipenem_NN for_IN empirical_JJ therapy_NN ._SENT Although_IN we_PP cannot_MD prove_VB this_DT hypothesis_NN ,_, the_DT immediate_JJ decline_NN in_IN imipenem_NN prescriptions_NNS by_IN more_JJR than_IN 80_CD %_NN after_IN the_DT introduction_NN of_IN written_VBN ,_, countersigned_VBD prescriptions_NNS supported_VBD the_DT assumption_NN that_IN ordering_VBG behavior_NN during_IN the_DT preceding_JJ period_NN had_VBD not_RB been_VBN dictated_VBN by_IN actual_JJ medical_JJ needs_NNS ._SENT In_IN addition_NN to_TO the_DT correlation_NN between_IN imipenem_NN use_NN and_CC resistance_NN of_IN P._NP aeruginosa_NP to_TO the_DT drug_NN itself_PP ,_, our_PP$ data_NNS also_RB revealed_VBD an_DT association_NN between_IN imipenem_NN consumption_NN and_CC resistance_NN to_TO ceftazidime_NN and_CC piperacillin-tazobactam_NN ._SENT In_IN contrast_NN ,_, rates_NNS of_IN consumption_NN of_IN ceftazidime_NN and_CC piperacillin-tazobactam_NN showed_VBD no_DT association_NN with_IN resistance_NN to_TO these_DT two_CD drugs_NNS ._SENT These_DT observations_NNS are_VBP in_IN accordance_NN with_IN data_NNS from_IN Carmeli_NP et_FW al._FW ,_, who_WP analyzed_VBD antibiotic_JJ treatment_NN courses_NNS in_IN individual_JJ patients_NNS suffering_VBG from_IN P._NP aeruginosa_NP infections_NNS ._SENT In_IN their_PP$ study_NN ,_, imipenem_NN therapy_NN was_VBD not_RB only_RB associated_VBN with_IN emergence_NN of_IN resistance_NN to_TO imipenem_VB (_( hazard_NN ratio_NN [_SYM HR_NP ]_SYM ,_, 44.0_CD compared_VBN to_TO other_JJ antipseudomonal_JJ drugs_NNS ;_: P_NN <_SYM 0.001_CD )_) ;_: it_PP also_RB had_VBD the_DT strongest_JJS association_NN with_IN emergence_NN of_IN resistance_NN to_TO any_DT of_IN the_DT antipseudomonal_JJ drugs_NNS under_IN study_NN ,_, which_WDT included_VBD piperacillin-tazobactam_NN and_CC ceftazidime_NN (_( HR_NP ,_, 2.9_CD ;_: P_NN <_SYM 0.008_CD )_) ._SENT By_IN contrast_NN ,_, patients_NNS treated_VBN with_IN piperacillin-tazobactam_NN or_CC ceftazidime_NN had_VBD no_DT significantly_RB increased_VBN risk_NN of_IN resistance_NN ._SENT Similarly_RB ,_, in_IN a_DT case_NN control_NN study_NN ,_, Troillet_NP et_FW al._FW analyzed_VBD 40_CD patients_NNS whose_WP$ first_JJ P._NP aeruginosa_NP isolate_NN was_VBD fully_RB or_CC intermediately_RB resistant_JJ to_TO imipenem_NN and_CC compared_VBN them_PP to_TO 387_CD control_NN patients_NNS harboring_VBG fully_RB susceptible_JJ strains_NNS ._SENT Pretreatment_NN with_IN imipenem_NN was_VBD identified_VBN as_IN the_DT major_JJ risk_NN factor_NN for_IN harboring_VBG a_DT resistant_JJ strain_NN (_( HR_NP ,_, 16.9_CD ;_: P_NN <_SYM 0.0001_CD )_) ,_, while_IN pretreatment_NN with_IN cephalosporins_NNS or_CC any_DT intravenous_JJ beta-lactam_NN was_VBD not_RB a_DT risk_NN factor_NN ._SENT Imipenem-resistant_JJ strains_NNS had_VBD a_DT 3.6-fold-higher_JJ rate_NN of_IN concomitant_JJ ceftazidime-resistance_NN ,_, and_CC a_DT 2.3-fold-higher_JJ rate_NN of_IN piperacillin-tazobactam_NN resistance_NN ,_, than_IN imipenem-sensitive_JJ strains_NNS ._SENT It_PP should_MD be_VB noted_VBN ,_, however_RB ,_, that_IN in_IN a_DT recent_JJ case_NN control_NN study_NN that_WDT included_VBD several_JJ different_JJ control_NN groups_NNS ,_, pretreatment_NN with_IN piperacillin-tazobactam_NN also_RB carried_VBD a_DT 2.4-fold-increased_JJ risk_NN for_IN isolation_NN of_IN an_DT imipenem-resistant_JJ P._NP aeruginosa_NP strain_NN ._SENT The_DT rapid_JJ emergence_NN of_IN resistance_NN in_IN clinical_JJ P._NP aeruginosa_NP isolates_VBZ during_IN imipenem_NN therapy_NN has_VBZ been_VBN well_RB described_VBN ._SENT Commonly_RB ,_, imipenem_NN resistance_NN in_IN this_DT species_NN is_VBZ due_JJ to_TO an_DT interplay_NN between_IN beta-lactamase_NN activity_NN and_CC reduced_VBN permeability_NN of_IN the_DT bacterial_JJ outer_JJ membrane_NN ,_, which_WDT results_VBZ from_IN the_DT loss_NN of_IN a_DT specific_JJ membrane_NN protein_NN ,_, the_DT OprD2_NP porin_NN ._SENT Treatment_NN with_IN other_JJ beta-lactam_NN drugs_NNS could_MD predispose_VB to_TO imipenem_NN resistance_NN by_IN selecting_VBG strains_NNS with_IN stably_RB derepressed_JJ beta-lactamase_NN production_NN ,_, which_WDT would_MD then_RB be_VB more_RBR likely_JJ to_TO lose_VB their_PP$ porin_NN OprD2_NN during_IN subsequent_JJ imipenem_NN therapy_NN ._SENT We_PP did_VBD not_RB analyze_VB the_DT mechanisms_NNS leading_VBG to_TO imipenem_NN and_CC beta-lactam_NN resistance_NN in_IN our_PP$ strains_NNS ._SENT However_RB ,_, given_VBN the_DT possibility_NN that_IN a_DT proportion_NN of_IN the_DT isolates_NNS were_VBD harbored_VBN by_IN the_DT patients_NNS during_IN their_PP$ prehospital_JJ phase_NN ,_, the_DT possibility_NN that_IN these_DT strains_NNS had_VBD been_VBN exposed_VBN to_TO beta-lactam_NN agents_NNS in_IN the_DT community_NN cannot_MD be_VB excluded_VBN ._SENT This_DT hypothesis_NN would_MD explain_VB both_CC the_DT rapid_JJ emergence_NN of_IN resistance_NN to_TO imipenem_NN and_CC the_DT concomitant_JJ beta-lactam_NN resistance_NN seen_VBN in_IN our_PP$ study_NN ._SENT Several_JJ limitations_NNS of_IN our_PP$ study_NN have_VB to_TO be_VB addressed_VBN ._SENT Firstly_RB ,_, a_DT more_RBR detailed_JJ analysis_NN of_IN resistance_NN in_IN primary_JJ and_CC secondary_JJ isolates_NNS would_MD have_VB been_VBN desirable_JJ ,_, in_IN particular_JJ during_IN the_DT first_JJ peak_NN of_IN imipenem_NN consumption_NN ._SENT During_IN the_DT second_JJ peak_NN ,_, the_DT analysis_NN showed_VBD that_IN horizontal_JJ transfers_NNS of_IN resistant_JJ strains_NNS apparently_RB played_VBD a_DT minor_JJ part_NN ,_, because_IN only_RB 9_CD %_NN of_IN primary_JJ isolates_NNS were_VBD imipenem-resistant_JJ ,_, in_IN contrast_NN to_TO 53.8_CD %_NN of_IN follow-up_NN isolates_NNS ._SENT Secondly_RB ,_, molecular_JJ typing_VBG was_VBD not_RB done_VBN ._SENT Demonstration_NN of_IN molecular_JJ strain_NN diversity_NN would_MD have_VB excluded_VBN a_DT common-source_NN clonal_JJ expansion_NN of_IN a_DT single_JJ strain_NN during_IN the_DT periods_NNS of_IN increased_VBN imipenem_NN resistance_NN ._SENT Lacking_VBG molecular_JJ data_NNS ,_, our_PP$ argument_NN against_IN the_DT assumption_NN of_IN a_DT clonal_JJ outbreak_NN is_VBZ that_IN every_DT physician_NN in_IN our_PP$ hospital_NN is_VBZ trained_VBN to_TO change_VB an_DT initial_JJ empirical_JJ antibiotic_JJ regimen_NN as_RB soon_RB as_IN microbiological_JJ tests_NNS showing_VBG resistance_NN to_TO the_DT empirically_RB used_VBN drug(s)_NN are_VBP available_JJ ._SENT Because_IN test_NN results_NNS were_VBD available_JJ within_IN 48_CD h_NN ,_, an_DT outbreak_NN of_IN primarily_RB imipenem-resistant_JJ strains_NNS would_MD have_VB led_VBN to_TO a_DT decrease_NN rather_RB than_IN an_DT increase_NN in_IN imipenem_NN consumption_NN ._SENT Further_JJR arguments_NNS against_IN an_DT outbreak_NN are_VBP the_DT time_NN course_NN between_IN use_NN and_CC resistance_NN ,_, regular_JJ visits_NNS of_IN an_DT experienced_JJ infection_NN control_NN team_NN to_TO all_DT wards_NNS ,_, and_CC the_DT absence_NN of_IN clustering_VBG of_IN P._NP aeruginosa_NP isolates_VBZ on_IN individual_JJ wards_NNS ._SENT Finally_RB ,_, had_VBD there_RB been_VBN an_DT outbreak_NN due_JJ to_TO an_DT unidentified_JJ lapse_NN in_IN hygiene_NN precautions_NNS ,_, restriction_NN of_IN imipenem_NN prescriptions_NNS as_IN the_DT only_JJ measure_NN taken_VBN would_MD not_RB have_VB resulted_VBN in_IN an_DT almost_RB immediate_JJ reversion_NN of_IN resistance_NN to_TO normal_JJ levels_NNS ._SENT A_DT third_JJ limitation_NN of_IN our_PP$ study_NN is_VBZ that_IN overall_JJ consumption_NN of_IN antibiotics_NNS varied_VBN significantly_RB ,_, although_IN this_DT was_VBD due_JJ mainly_RB to_TO variations_NNS in_IN imipenem_NN usage_NN ._SENT It_PP is_VBZ possible_JJ that_IN any_DT other_JJ agent_NN in_IN the_DT place_NN of_IN imipenem_NN might_MD have_VB been_VBN associated_VBN with_IN similar_JJ phenomena_NNS of_IN resistance_NN ._SENT Therefore_RB ,_, we_PP believe_VBP that_IN our_PP$ study_NN provides_VBZ an_DT argument_NN for_IN a_DT regulated_JJ ,_, preferably_RB written_VBN antibiotic_JJ policy_NN which_WDT balances_VBZ the_DT use_NN of_IN individual_JJ antibiotics_NNS ._SENT Most_RBS likely_RB ,_, such_PDT a_DT policy_NN will_MD prevent_VB the_DT occurrence_NN of_IN major_JJ disturbances_NNS of_IN a_DT hospital_NN 's_POS microbial-sensitivity_NN patterns_NNS by_IN unrestricted_JJ use_NN of_IN particular_JJ agents_NNS ._SENT 